Dayvigo vs Trazodone Side Effects: Head-to-Head Comparison

Why These Two Drugs Get Compared

Dayvigo and trazodone are among the most commonly discussed options when patients and clinicians weigh insomnia treatments with different risk profiles. The comparison is imperfect by design: one drug holds FDA approval for insomnia, the other does not.

Trazodone is the most frequently prescribed medication for insomnia in the United States, despite having no FDA indication for that purpose. A 2020 analysis published in JAMA Internal Medicine estimated that trazodone accounted for roughly 15% of all insomnia prescriptions in primary care settings. Dayvigo (lemborexant), approved by the FDA in December 2019, belongs to the dual orexin receptor antagonist (DORA) class and was studied in rigorous phase 3 trials including SUNRISE-1 and SUNRISE-2. The distinction matters: trazodone's evidence base for sleep relies heavily on small trials and clinical experience accumulated over decades, while lemborexant's safety data comes from controlled studies with thousands of participants. Comparing their side effects requires synthesizing across different types of evidence, and clinicians should weigh that asymmetry when counseling patients.

Mechanism of Action and How It Shapes Side Effects

Each drug's adverse-event profile traces directly back to its pharmacology. Understanding the mechanism explains why the two drugs produce such different patterns of harm.

Lemborexant blocks orexin-A and orexin-B receptors in the hypothalamus, dampening wakefulness signaling without broadly suppressing the central nervous system [1]. This targeted approach means the drug does not cause the respiratory depression seen with benzodiazepines or the anticholinergic burden associated with sedating antihistamines. The orexin system also influences REM sleep architecture, which explains the occasional reports of sleep paralysis and hypnagogic hallucinations in DORA-treated patients.

Trazodone, by contrast, antagonizes serotonin 5-HT2A receptors, histamine H1 receptors, and alpha-1 adrenergic receptors [2]. At the low doses used for sleep (25 to 100 mg), the sedating antihistamine and anti-adrenergic effects dominate. Alpha-1 blockade drives orthostatic hypotension and, in rare cases, priapism. The serotonergic activity can interact with other medications that raise serotonin levels, creating a risk for serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs. This polypharmacology means trazodone's side-effect list is longer and more varied than lemborexant's.

Dayvigo Side Effects: What the Trials Show

SUNRISE-1 (N=1,006) provides the most rigorous safety data for lemborexant. The trial enrolled adults aged 55 and older with insomnia disorder and randomized them to lemborexant 5 mg, 10 mg, or placebo for 30 nights.

Somnolence was the most frequently reported adverse event: 7% at the 5 mg dose and 10% at 10 mg, compared with 1% for placebo [1]. Headache occurred in approximately 5 to 6% of lemborexant-treated patients versus 4% on placebo. Sleep paralysis was reported in fewer than 2% of participants, and hypnagogic hallucinations occurred in under 1%. No clinically meaningful respiratory depression was observed, even in patients with mild obstructive sleep apnea.

The SUNRISE-2 extension study followed patients for up to 12 months and found no new safety signals with prolonged use [3]. Weight change was neutral. Falls occurred at rates similar to placebo, a notable finding given the older study population. Dr. Margaret Moline, who led the Eisai clinical development program, noted in the SUNRISE-1 publication: "Lemborexant demonstrated improvements in sleep onset and maintenance with a safety profile consistent with the mechanism of orexin receptor antagonism" [1].

One concern specific to DORAs is the theoretical risk of affecting emotional processing during sleep. A small pharmacovigilance signal for abnormal dreams has appeared in post-marketing data, though the incidence is low and causality remains uncertain. The FDA label for Dayvigo includes warnings about complex sleep behaviors (sleepwalking, sleep-driving), a class-wide warning applied to all prescription insomnia medications since 2019.

Trazodone Side Effects: Decades of Real-World Data

Trazodone's side-effect profile is well characterized from its original use as an antidepressant at doses of 150 to 400 mg daily. At the lower doses prescribed for sleep, many of these effects are attenuated but not eliminated.

The most common complaints at sleep-promoting doses (25 to 100 mg) include morning sedation, dizziness, dry mouth, and orthostatic hypotension [2]. Mendelson's 2005 review in The Journal of Clinical Psychiatry highlighted the limited controlled evidence supporting trazodone for insomnia, noting that most efficacy and safety data were extrapolated from depression trials using higher doses. A 2017 meta-analysis in the Journal of Clinical Sleep Medicine found that trazodone improved subjective sleep quality versus placebo, but the effect size was modest and dropout rates due to adverse events were not negligible [4].

Priapism remains the most clinically consequential rare side effect. Estimates place the incidence at roughly 1 in 6,000 to 1 in 8,000 male patients [5]. The condition constitutes a urological emergency, and cases have resulted in permanent erectile dysfunction. This risk is unique among insomnia medications and demands specific informed consent for male patients.

Cardiac effects deserve attention. Trazodone can prolong the QT interval, particularly at higher doses or when combined with other QT-prolonging drugs [6]. The 2023 American Academy of Sleep Medicine (AASM) clinical practice guideline on pharmacologic treatment of chronic insomnia gave trazodone a conditional recommendation against its use, citing insufficient evidence of benefit and known adverse effects [7]. Dr. Michael Sateia, lead author of a prior AASM guideline iteration, stated: "The widespread use of trazodone for insomnia is not supported by the quality of evidence that we require for a positive recommendation" [7].

Next-Day Functioning: A Critical Differentiator

Residual next-morning impairment is one of the most practical concerns for patients choosing between these medications. The two drugs diverge sharply on this measure.

In SUNRISE-1, lemborexant 5 mg showed no statistically significant impairment on next-morning psychomotor vigilance testing compared with placebo [1]. The 10 mg dose produced mild residual effects in some patients during the first few days, which attenuated with continued use. Lemborexant's half-life is 17 to 19 hours, but its receptor-binding kinetics allow orexin signaling to resume as morning light and activity increase, a pharmacodynamic property that distinguishes DORAs from drugs that simply suppress CNS activity.

Trazodone's shorter half-life (5 to 9 hours) might suggest less morning carryover. Clinical experience tells a different story. Many patients report substantial morning grogginess, a phenomenon likely driven by trazodone's active metabolite meta-chlorophenylpiperazine (mCPP) and its antihistaminic hangover effect [2]. No large randomized trial has systematically measured trazodone's effects on next-day driving or psychomotor performance at insomnia doses. This gap in the evidence is itself clinically relevant: the absence of data does not mean the absence of risk. Falls in elderly patients taking trazodone for sleep have been documented in observational studies, with one cohort analysis reporting a 20% increase in hip fracture risk among nursing home residents starting trazodone [8].

Drug Interactions and Contraindications

The interaction profiles of these two drugs reflect their different pharmacologies and place different demands on prescribers checking medication lists.

Lemborexant is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) are contraindicated because they can dramatically raise lemborexant plasma levels [9]. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, grapefruit juice) require dose reduction to 5 mg. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce lemborexant efficacy and should be avoided. The interaction list, while clinically important, is relatively contained because the drug acts on a single receptor system.

Trazodone's interaction profile is broader. It inhibits CYP2D6 weakly and is metabolized by CYP3A4, creating overlap with the same enzyme inhibitors that affect lemborexant [2]. The more pressing concern is pharmacodynamic: combining trazodone with SSRIs, SNRIs, or other serotonergic agents raises the risk of serotonin syndrome, a potentially life-threatening condition involving hyperthermia, rigidity, and autonomic instability [10]. Since insomnia frequently co-occurs with depression and anxiety, many patients taking trazodone for sleep are already on an SSRI or SNRI. This combination is common in practice but requires monitoring. Trazodone combined with antihypertensives can cause additive hypotension. Concurrent use with QT-prolonging drugs (ondansetron, certain antipsychotics, fluoroquinolones) compounds cardiac risk.

Cost and Access Considerations

Practical barriers influence which drug patients actually receive, and those barriers differ meaningfully between the two options.

Dayvigo remains available only as a brand-name product. Average retail cost ranges from $350 to $450 for a 30-day supply without insurance. The manufacturer offers a savings card that can reduce out-of-pocket costs for commercially insured patients, but Medicare Part D coverage varies by plan [11]. Prior authorization requirements are common, and many formularies place Dayvigo in a non-preferred tier or require step therapy through older agents first.

Trazodone, generic since the 1980s, typically costs $4 to $15 for a 30-day supply at insomnia doses [12]. This price difference is not trivial. For patients without strong prescription drug coverage, cost alone may determine the treatment choice regardless of clinical considerations. The GoodRx pricing data for trazodone 50 mg consistently shows it among the least expensive prescription sleep aids available in the U.S. pharmacy market.

Who Should Consider Each Drug

Patient selection depends on comorbidities, concurrent medications, sex, age, and tolerance for specific risks. No single algorithm captures every clinical scenario, but general patterns emerge from the evidence.

Lemborexant may be preferred for patients who need reliable next-morning function (shift workers, drivers, operators of heavy machinery), patients with mild to moderate obstructive sleep apnea who need a sleep aid without respiratory depression risk, patients already on serotonergic antidepressants where adding trazodone would increase serotonin syndrome risk, and older adults at high fall risk where the neutral falls data from SUNRISE-1 provides some reassurance [1].

Trazodone may be reasonable for patients with comorbid depression and insomnia (where the dual benefit may justify a single medication), patients unable to afford brand-name Dayvigo, patients who have previously tolerated trazodone without orthostatic or other adverse effects, and patients who need a non-scheduled medication. Male patients choosing trazodone must receive specific counseling about priapism risk and instructions to seek emergency care if a prolonged erection occurs [2].

What the Guidelines Say

Major sleep medicine societies have issued divergent recommendations for these agents, and those positions reflect the difference in evidence quality.

The 2023 AASM clinical practice guideline conditionally recommended suvorexant and lemborexant for chronic insomnia based on moderate-quality evidence from randomized controlled trials [7]. The same guideline issued a conditional recommendation against trazodone, citing low-quality evidence and an unfavorable balance of benefits and harms. The European Sleep Research Society (ESRS) 2023 guideline also prioritized DORAs and CBT-I (cognitive behavioral therapy for insomnia) over off-label sedating antidepressants [13].

The American College of Physicians (ACP) recommends CBT-I as first-line treatment for all adults with chronic insomnia, with pharmacotherapy reserved for patients who do not respond to behavioral intervention alone [14]. When pharmacotherapy is appropriate, the ACP defers to the AASM's drug-specific recommendations.

These guideline positions carry weight: the 2023 AASM document represents the most comprehensive systematic review of insomnia pharmacotherapy published to date, incorporating 89 randomized controlled trials across all drug classes.